|
Jul 25
|
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
|
|
Jul 24
|
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Jul 23
|
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
|
|
Jul 18
|
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
|
|
Jul 15
|
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
|
|
Jun 30
|
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
|
|
Mar 29
|
Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
|
|
Mar 29
|
Humacyte price target lowered to $8 from $10 at BTIG
|
|
Mar 3
|
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
|
|
Feb 27
|
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
|
|
Feb 27
|
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
|
|
Feb 26
|
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
|
|
Sep 26
|
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
|
|
Aug 27
|
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
|
|
Jul 16
|
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
|
|
Jun 25
|
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
|
|
Jun 17
|
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
|
|
May 13
|
Humacyte to Participate at Upcoming Investor Conferences in May
|
|
May 10
|
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances
|
|
May 10
|
Humacyte First Quarter 2024 Financial Results and Business Update
|